Structural Diversity Problems and the Solving Method for Antibody Light Chains
暂无分享,去创建一个
R. Kato | H. Taguchi | T. Uda | M. Arakawa | E. Hifumi | YoshikiKatayama
[1] R. Kato,et al. Role of the constant region domain in the structural diversity of human antibody light chains , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] M. Guerreiro,et al. Trastuzumab in the Treatment of Breast Cancer , 2016, BioDrugs.
[3] S. Matsumoto,et al. A novel method of preparing the monoform structure of catalytic antibody light chain , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] S. Matsumoto,et al. Biochemical features and antiviral activity of a monomeric catalytic antibody light‐chain 23D4 against influenza A virus , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] A. Pattanayak,et al. Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer’s Disease: Prophylactic and Therapeutic Applications , 2015, Molecular Neurobiology.
[6] Y. Nishiyama,et al. Metal-dependent amyloid β-degrading catalytic antibody construct. , 2014, Journal of biotechnology.
[7] C. Noe,et al. Quality Control and Stability Studies with the Monoclonal Antibody, Trastuzumab: Application of 1D- vs. 2D-Gel Electrophoresis , 2014, International journal of molecular sciences.
[8] S. Matsumoto,et al. Biochemical Features of a Catalytic Antibody Light Chain, 22F6, Prepared from Human Lymphocytes* , 2013, The Journal of Biological Chemistry.
[9] A. Nishizono,et al. Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] C. Noe,et al. Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab. , 2011, Journal of pharmaceutical and biomedical analysis.
[11] V. Buneva,et al. Affinity and catalytic heterogeneity and metal‐dependence of polyclonal myelin basic protein‐hydrolyzing IgGs from sera of patients with systemic lupus erythematosus , 2011, Journal of molecular recognition : JMR.
[12] Nikita Kuznetsov,et al. Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics , 2011, Proceedings of the National Academy of Sciences.
[13] M. Sawyer,et al. Critical appraisal of trastuzumab in treatment of advanced stomach cancer , 2011, Cancer management and research.
[14] K. Higashi,et al. Catalytic digestion of human tumor necrosis factor‐α by antibody heavy chain , 2010, The FEBS journal.
[15] Naoko Fujimoto,et al. Characteristic features of InfA-15 monoclonal antibody recognizing H1, H3, and H5 subtypes of hemagglutinin of influenza virus A type. , 2010, Journal of bioscience and bioengineering.
[16] V. Buneva,et al. DNA-hydrolyzing activity of IgG antibodies from the sera of patients with tick-borne encephalitis. , 2010, Biochimie.
[17] O. M. Durova,et al. Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. , 2009, Molecular immunology.
[18] S. Kaveri,et al. Factor VIII‐hydrolyzing IgG in acquired and congenital hemophilia , 2009, FEBS letters.
[19] Yasuhiro Nishiyama,et al. Catalytic antibodies to HIV: physiological role and potential clinical utility. , 2008, Autoimmunity reviews.
[20] A. Nishizono,et al. Catalytic Features and Eradication Ability of Antibody Light-chain UA15-L against Helicobacter pylori* , 2008, Journal of Biological Chemistry.
[21] C. Slaughter,et al. Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. , 2006, The Biochemical journal.
[22] O. Favorova,et al. Amylolytic activity of IgM and IgG antibodies from patients with multiple sclerosis. , 2003, Immunology letters.
[23] T. Uda,et al. Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain. , 2002, Journal of immunological methods.
[24] N. Jaffrezic‐Renault,et al. Investigating antibody-antigen binding with atomic force microscopy , 2002 .
[25] B. Kabakoff,et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[26] S. Kaveri,et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A , 1999, Nature Medicine.
[27] A. Vlassov,et al. Catalytic DNA-and RNA-hydrolyzing antibodies from milk of healthy human mothers , 1998, Applied biochemistry and biotechnology.
[28] K. Yoshida,et al. DNA-hydrolyzing activity of Bence Jones proteins. , 1998, Biochemical and biophysical research communications.
[29] A. Chen,et al. Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. , 1996, Journal of chromatography. A.
[30] R. Radulescu. Antibody constant region: potential to bind metal and nucleic acid. , 1995, Medical hypotheses.
[31] C. Chang,et al. Dual conformations of an immunoglobulin light-chain dimer: heterogeneity of antigen specificity and idiotope profile may result from multiple variable-domain interaction mechanisms. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[32] E. Odintsova,et al. Metal dependent hydrolysis of β‐casein by sIgA antibodies from human milk , 2011, Journal of molecular recognition : JMR.
[33] M. Glassy,et al. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. , 2009, Human antibodies.
[34] A. Edmundson,et al. Naturally Occurring Proteolytic Antibodies SELECTIVE IMMUNOGLOBULIN M-CATALYZED HYDROLYSIS OF HIV gp120* , 2004 .